M&A / Deals Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B BioPharma DiveAssertio s latest offer represents a roughly 31% premium over an initial acquisition proposal.Read full story pharminent May 13, 2026 (Last updated: May 13, 2026) BioPharma Dive Assertio s latest offer represents a roughly 31% premium over an initial acquisition proposal. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: ECO 2026: REDEFINE-1 demonstrates CagriSema’s improvement in body compositionNext: UniQure, Replimune shares rise as FDA’s Makary exits, but path forward unchanged Related Stories M&A / Deals Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar pharminent July 10, 2026 M&A / Deals GSK ends dementia alliance with Alector after setbacks pharminent July 9, 2026 M&A / Deals AstraZeneca, GSK intensify China ties with Sino Biopharm deals pharminent July 8, 2026
